Mirati Therapeutics Management

Management criteria checks 3/4

Mirati Therapeutics' CEO is Chuck Baum, appointed in Nov 2012, has a tenure of 11.17 years. total yearly compensation is $7.42M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth R$32.75M. The average tenure of the management team and the board of directors is 2.5 years and 5.1 years respectively.

Key information

Chuck Baum

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage	9.2%
CEO tenure	11.2yrs
CEO ownership	0.2%
Management average tenure	2.5yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chuck Baum's remuneration changed compared to Mirati Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$726m
Jun 30 2023	n/a	n/a	-US$738m
Mar 31 2023	n/a	n/a	-US$737m
Dec 31 2022	US$7m	US$685k	-US$741m
Sep 30 2022	n/a	n/a	-US$738m
Jun 30 2022	n/a	n/a	-US$645m
Mar 31 2022	n/a	n/a	-US$634m
Dec 31 2021	US$18m	US$662k	-US$582m
Sep 30 2021	n/a	n/a	-US$483m
Jun 30 2021	n/a	n/a	-US$491m
Mar 31 2021	n/a	n/a	-US$407m
Dec 31 2020	US$12m	US$615k	-US$358m
Sep 30 2020	n/a	n/a	-US$329m
Jun 30 2020	n/a	n/a	-US$296m
Mar 31 2020	n/a	n/a	-US$259m
Dec 31 2019	US$8m	US$597k	-US$213m
Sep 30 2019	n/a	n/a	-US$169m
Jun 30 2019	n/a	n/a	-US$142m
Mar 31 2019	n/a	n/a	-US$125m
Dec 31 2018	US$5m	US$580k	-US$98m
Sep 30 2018	n/a	n/a	-US$88m
Jun 30 2018	n/a	n/a	-US$77m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$2m	US$563k	-US$70m

Compensation vs Market: Chuck's total compensation ($USD7.42M) is above average for companies of similar size in the BR market ($USD1.68M).

Compensation vs Earnings: Chuck's compensation has been consistent with company performance over the past year.

CEO

Chuck Baum (65 yo)

11.2yrs

Tenure

US$7,420,213

Compensation

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% R$ 32.8m
James Christensen	Executive VP & Chief Scientific Officer	10yrs	US$5.01m	0.082% R$ 16.8m
Alan Bart Sandler	Executive VP & Chief Medical Officer	1.2yrs	US$5.30m	0.014% R$ 2.9m
Aaron Ondrey	Chief Financial Officer	less than a year	no data	0.056% R$ 11.5m
Betsy Gelfand	Chief Accounting Officer	less than a year	no data	no data
John Moriarty	Chief Legal Officer & Corporate Secretary	less than a year	no data	no data
Peter Lee	Chief Compliance Officer	2yrs	no data	no data
Michael Paolucci	Chief People Officer	2yrs	no data	no data
Benjamin Hickey	Chief Commercial Officer	4yrs	US$6.93m	0.040% R$ 8.1m
Kelly Covello	VP & Head of Medical Affairs	3.8yrs	no data	no data
Ryan Asay	VP & Head of Corporate Affairs	3.8yrs	no data	no data
Susan Welsh	Senior VP of Pharmacovigilance & Chief Safety Officer	3yrs	no data	no data

2.5yrs

Average Tenure

55yo

Average Age

Experienced Management: M2RT34's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% R$ 32.8m
Bruce Leonard Carter	Independent Director	7.3yrs	US$700.41k	0.0086% R$ 1.8m
George Demetri	Member of Scientific Advisory Board	no data	no data	no data
Faheem Hasnain	Chairman & Lead Independent Director	4.9yrs	US$979.79k	0.012% R$ 2.6m
Julie Michele Cherrington	Independent Director	4.6yrs	US$697.91k	0% R$ 0
Stephen Baylin	Member of Scientific Advisory Board	no data	no data	no data
Lillian Siu	Member of Scientific Advisory Board	no data	no data	no data
Aaron Davis	Independent Director	5.1yrs	US$677.91k	0.061% R$ 12.6m
Pasi Antero Janne	Member of Scientific Advisory Board	5yrs	no data	no data
Craig Johnson	Independent Director	10.3yrs	US$702.91k	0.0086% R$ 1.8m
Channing Der	Member of Scientific Advisory Board	5yrs	no data	no data
Maria Martinez-Davis	Independent Director	5.1yrs	US$695.41k	0.0086% R$ 1.8m

5.1yrs

Average Tenure

65yo

Average Age

Experienced Board: M2RT34's board of directors are considered experienced (5.1 years average tenure).

Mirati Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age